Showing results (1-10 of 272) with videos related to
Sort By:
Pageof 28
Expert Opinion on Therapeutic Targets|October 15, 2008
Challenges in developing targeted therapy for pancreatic adenocarcinomaDevalingam Mahalingam, Francis GilesDrug Design, Development and Therapy|November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinibRonan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.European Journal of Cancer (Oxford, England : 1990)|October 10, 2009
Cdc7 kinase - a new target for drug developmentRonan Swords, Devalingam Mahalingam, Michael O'Dwyer, et al.Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.Journal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to responseAri Rosenberg, Devalingam MahalingamJournal of Gastrointestinal Oncology|March 23, 2018
Immunotherapy in colorectal cancer: for the select few or all?Sukeshi Patel Arora, Devalingam MahalingamOncotarget|December 20, 2017
Review: Oncolytic virotherapy, updates and future directionsChristos Fountzilas, Sukeshi Patel, Devalingam MahalingamCancers|April 12, 2020
The Landscape of Targeted Therapies in TNBCElena Vagia, Devalingam Mahalingam, Massimo CristofanilliPageof 28